Connecting Healthcare - Healthcare Communications Network

Peer-influenced content. Sources you trust. No registration required. This is HCN.

Essential Medical Reading

Your Weekly Roundup of the Most-Read News and Clinical References from Your Peers

FDA Approval of Milsaperidone Widens Door to Severe Mental Disorder Treatment

The new chemical entity is an atypical antipsychotic and the active metabolite of iloperidone (Fanapt). Its ability to cross the blood-brain barrier likely contributes to iloperidone’s clinical effects.

Psychiatry March 4th 2026

Tags: ANTIPSYCHOTICS BIPOLAR DISORDER DEVICE/DRUG APPROVALS FDA SCHIZOPHRENIA

Psychiatrist.com

Postmarketing Safety of Transcranial Magnetic Stimulation: A 10-Year MAUDE Database Analysis of Adverse Events and Technological Advancements

The objective of the study was to characterize the real-world safety profile of TMS devices based on MAUDE-reported AEs, including symptom patterns, manufacturer-level variations, device issues, and reporting delays.

Psychiatry March 4th 2026

Tags: ADDICTION MEDICINE ADVERSE EVENTS EPILEPSY/SEIZURES NEUROMODULATION PAIN MANAGEMENT PATIENT SAFETY TRANSCRANIAL MAGNETIC STIMULATION (TMS)

Psychiatry Advisor

Dialectical Behavior Therapy Reduces Symptoms in Borderline Personality Disorder

The study authors noted that DBT was more effective than SSRI/M for reducing suicide-related and self-injurious behaviors during the 6-month treatment phase, though differences were not sustained at 12 months.

Psychiatry March 4th 2026

Tags: DIALECTICAL BEHAVIOR THERAPY (DBT) PERSONALITY DISORDERS PSYCHOLOGY SOCIAL WORK SUICIDE

Journal of Attention Disorders (JAD)

Miss. Diagnosis: A Systematic Review of ADHD in Adult Women

“Women and girls are too often suffering in silence, being left out of the ADHD narrative.” — Attoe & Climie, Journal of Attention Disorders, 2023

Psychiatry March 4th 2026

Tags: ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) GENDER DISPARITIES MENTAL HEALTH MISDIAGNOSIS WOMEN'S HEALTH

Psych Congress Network

Synthetic Psilocybin Meets Primary Endpoint in Phase 3 Treatment-Resistant Depression Trial

“TRD patients have extremely limited treatment options, and the unmet need remains profound.” — Guy Goodwin, MD, CMO, Compass Pathways

Psychiatry March 4th 2026

Tags: ADDICTION MEDICINE DEPRESSION PALLIATIVE CARE PSYCHEDELICS RESEARCH & CLINICAL TRIALS

Oncology News Central (ONC)

Oncology Reimbursement Undergoes “Significant Overhaul”: 9 Critical Changes to Know

“When 60% of ‘not medically necessary’ denials are reversed…we’re seeing algorithmic denial for delay’s sake.” — Anthony J. Paravati, MD, Kettering Health

Hematology/Oncology March 3rd 2026

Tags: BUSINESS & POLICY CODING & REIMBURSEMENT GENETIC TESTING INSURANCE

1 2 … 747 748 >>

Trending Topics:

Essential Medical Reading

FDA Approval of Milsaperidone Widens Door to Severe Mental Disorder Treatment

Postmarketing Safety of Transcranial Magnetic Stimulation: A 10-Year MAUDE Database Analysis of Adverse Events and Technological Advancements

Dialectical Behavior Therapy Reduces Symptoms in Borderline Personality Disorder

Miss. Diagnosis: A Systematic Review of ADHD in Adult Women

Synthetic Psilocybin Meets Primary Endpoint in Phase 3 Treatment-Resistant Depression Trial

Oncology Reimbursement Undergoes “Significant Overhaul”: 9 Critical Changes to Know

Topics

Sources

The Healthcare Communications Network is owned and operated by IQVIA Inc. Click below to leave this site and continue to IQVIA’s Privacy Choices form

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form